In CRC, metabolic reprogramming exhibits significant stage-dependent dynamics: early-stage tumors primarily activate glycolysis (15), while in advanced stages, tumors display various metabolic abnormalities, with lipid metabolism disorders (such as overexpression of fatty acid synthase, FASN) becoming increasingly prominent (16, 17). The gene discussed is FASN; the disease is Disorder of lipid metabolism.